Phase III prostate cancer chemoprevention trials

Howard L. Parnes, Otis Brawley, Lori M. Minasian, Leslie G. Ford

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Chemoprevention refers to the use of pharmacologic interventions to delay, prevent, or reverse carcinogenesis with the ultimate goal of reducing cancer incidence. Two large, population-based, phase 3 prostate cancer prevention trials reported that 5-alpha reductase inhibitors significantly reduce prostate cancer risk. However, this class of agents were also associated with increased detection of high-grade prostate cancer. Another large, phase 3 prostate cancer prevention clinical trial showed no benefit for long-term supplementation with the trace element Se, given in the form of selenomethionine, or vitamin E, either individually or in combination. Paradoxically, a significant increase in prostate cancer was observed among men randomized to receive vitamin E alone. A great deal of progress had been made in the field of prostate cancer prevention over the past decade. Future studies will focus on prevention of disease progression in men on Active Surveillance, immunotherapy, mechanistically based drug combinations, and novel biomarkers of risk and benefit.

Original languageEnglish (US)
Title of host publicationProstate Cancer Prevention
PublisherSpringer New York LLC
Pages73-77
Number of pages5
ISBN (Print)9783642451942
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Publication series

NameRecent Results in Cancer Research
Volume202
ISSN (Print)0080-0015

Fingerprint

Chemoprevention
Prostatic Neoplasms
Vitamin E
5-alpha Reductase Inhibitors
Selenomethionine
Active Immunotherapy
Trace Elements
Drug Combinations
Disease Progression
Carcinogenesis
Biomarkers
Clinical Trials
Incidence
Population
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Parnes, H. L., Brawley, O., Minasian, L. M., & Ford, L. G. (2014). Phase III prostate cancer chemoprevention trials. In Prostate Cancer Prevention (pp. 73-77). (Recent Results in Cancer Research; Vol. 202). Springer New York LLC. https://doi.org/10.1007/978-3-642-45195-9_9

Phase III prostate cancer chemoprevention trials. / Parnes, Howard L.; Brawley, Otis; Minasian, Lori M.; Ford, Leslie G.

Prostate Cancer Prevention. Springer New York LLC, 2014. p. 73-77 (Recent Results in Cancer Research; Vol. 202).

Research output: Chapter in Book/Report/Conference proceedingChapter

Parnes, HL, Brawley, O, Minasian, LM & Ford, LG 2014, Phase III prostate cancer chemoprevention trials. in Prostate Cancer Prevention. Recent Results in Cancer Research, vol. 202, Springer New York LLC, pp. 73-77. https://doi.org/10.1007/978-3-642-45195-9_9
Parnes HL, Brawley O, Minasian LM, Ford LG. Phase III prostate cancer chemoprevention trials. In Prostate Cancer Prevention. Springer New York LLC. 2014. p. 73-77. (Recent Results in Cancer Research). https://doi.org/10.1007/978-3-642-45195-9_9
Parnes, Howard L. ; Brawley, Otis ; Minasian, Lori M. ; Ford, Leslie G. / Phase III prostate cancer chemoprevention trials. Prostate Cancer Prevention. Springer New York LLC, 2014. pp. 73-77 (Recent Results in Cancer Research).
@inbook{e0a894ff0bfe4cbe96e3ee54e31b6e59,
title = "Phase III prostate cancer chemoprevention trials",
abstract = "Chemoprevention refers to the use of pharmacologic interventions to delay, prevent, or reverse carcinogenesis with the ultimate goal of reducing cancer incidence. Two large, population-based, phase 3 prostate cancer prevention trials reported that 5-alpha reductase inhibitors significantly reduce prostate cancer risk. However, this class of agents were also associated with increased detection of high-grade prostate cancer. Another large, phase 3 prostate cancer prevention clinical trial showed no benefit for long-term supplementation with the trace element Se, given in the form of selenomethionine, or vitamin E, either individually or in combination. Paradoxically, a significant increase in prostate cancer was observed among men randomized to receive vitamin E alone. A great deal of progress had been made in the field of prostate cancer prevention over the past decade. Future studies will focus on prevention of disease progression in men on Active Surveillance, immunotherapy, mechanistically based drug combinations, and novel biomarkers of risk and benefit.",
author = "Parnes, {Howard L.} and Otis Brawley and Minasian, {Lori M.} and Ford, {Leslie G.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-3-642-45195-9_9",
language = "English (US)",
isbn = "9783642451942",
series = "Recent Results in Cancer Research",
publisher = "Springer New York LLC",
pages = "73--77",
booktitle = "Prostate Cancer Prevention",

}

TY - CHAP

T1 - Phase III prostate cancer chemoprevention trials

AU - Parnes, Howard L.

AU - Brawley, Otis

AU - Minasian, Lori M.

AU - Ford, Leslie G.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Chemoprevention refers to the use of pharmacologic interventions to delay, prevent, or reverse carcinogenesis with the ultimate goal of reducing cancer incidence. Two large, population-based, phase 3 prostate cancer prevention trials reported that 5-alpha reductase inhibitors significantly reduce prostate cancer risk. However, this class of agents were also associated with increased detection of high-grade prostate cancer. Another large, phase 3 prostate cancer prevention clinical trial showed no benefit for long-term supplementation with the trace element Se, given in the form of selenomethionine, or vitamin E, either individually or in combination. Paradoxically, a significant increase in prostate cancer was observed among men randomized to receive vitamin E alone. A great deal of progress had been made in the field of prostate cancer prevention over the past decade. Future studies will focus on prevention of disease progression in men on Active Surveillance, immunotherapy, mechanistically based drug combinations, and novel biomarkers of risk and benefit.

AB - Chemoprevention refers to the use of pharmacologic interventions to delay, prevent, or reverse carcinogenesis with the ultimate goal of reducing cancer incidence. Two large, population-based, phase 3 prostate cancer prevention trials reported that 5-alpha reductase inhibitors significantly reduce prostate cancer risk. However, this class of agents were also associated with increased detection of high-grade prostate cancer. Another large, phase 3 prostate cancer prevention clinical trial showed no benefit for long-term supplementation with the trace element Se, given in the form of selenomethionine, or vitamin E, either individually or in combination. Paradoxically, a significant increase in prostate cancer was observed among men randomized to receive vitamin E alone. A great deal of progress had been made in the field of prostate cancer prevention over the past decade. Future studies will focus on prevention of disease progression in men on Active Surveillance, immunotherapy, mechanistically based drug combinations, and novel biomarkers of risk and benefit.

UR - http://www.scopus.com/inward/record.url?scp=84958551262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958551262&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-45195-9_9

DO - 10.1007/978-3-642-45195-9_9

M3 - Chapter

C2 - 24531780

AN - SCOPUS:84958551262

SN - 9783642451942

T3 - Recent Results in Cancer Research

SP - 73

EP - 77

BT - Prostate Cancer Prevention

PB - Springer New York LLC

ER -